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Abstract 
   
Cryptococcus neoformans causes both pulmonary and meninges infection in healthy 
and immunocompromised hosts. The objective of this study was to determine the prevalence 
of pulmonary cryptococcosis in HIV/AIDS patients and assess the clinical presentations due 
to the infection. The subjects recruited for this study were confirmed HIV/AIDS patients, 
presenting with pneumonia complications. The demographic and clinical features were 
abstracted from the medical records and administered questionnaire. Early morning sputum 
samples were collected from the patients and examined by bacteriological methods. The 
isolated Cryptococcus neoformans were sub-cultured onto thistle bird seed agar and the 
identity was confirmed with API 20C Kit. Out of 250 patients investigated, 47 (18.8%) had 
pulmonary cryptococcosis. The C.neoformans isolates were more in females, 26 (10.4%) than 
the males, 21 (8.4%), while the age group of 20-40 years old had 39 (15.6%) isolates. The 
clinical features that were associated with the pulmonary cryptococcosis were the production 
of purulent and bloody sputum, and fever. The patients with prolonged duration of HIV/AIDS 
and are not on HAART regimens had higher C.neoformans isolates. The isolation of 
C.neoformans from HIV/AIDS patients is a major public health concern, since it complicates 
the severity of the disease. There is a need for routine check of pulmonary cryptococcosis, 
especially, in those who do not avail themselves for antiretroviral therapy. 
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Introduction 
 
Infections due to Cryptococcus neoformans occurs world wide without any specific 
endemic areas. The fungus is an ubiquitous pathogenic encapsulated yeast, classified as 
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Basichomy cota (Levitz, 1991). Human diseases caused by the fungus range from 
asymptomatic pulmonary colonization to life threatening meningitis and overwhelming 
cryptococcemia (Levitz, 1991; Duperval et al, 1977; Perfect et al, 1983). The mode of entry 
into a new host is through the respiratory tract.  
Cryptococcosis occurs in healthy hosts, but majority has significant underlying 
predisposing factors especially in advanced HIV disease and transplant related 
immunosuppression. (Thomas et al, 1998; Aberg et al; Pappas et al, 2001; Dismukes, 1998) In 
immunocompromised patients, cryptococcosis can be severe and rapidly progressive; 
requiring prolonged systemic antifungal therapy (Dismukes, 1993; Saag et al, 2000). The 
infection is the most common life-threatening disease in HIV patients, and extra- pulmonary 
cryptococcosis is an AIDS- defining illness. The clinical presentation includes disseminated 
meningo-encephalitis, which is rapidly fatal in the absence of therapy (Mwaba et al, 2001; 
Dupont et al, 2000; Heyderman et al, 1998).  Cryptococcosis in HIV/AIDS patients varies 
from <1.0 to 10% in western countries (Knight et al, 1993; Burckhardt et al,1999) to more 
than 33% in sub-Saharan Africa and South east Asia (Mwaba et al, 2001; Hakim et al, 2000). 
This presents with high morbidity in HIV/AIDS patients in sub-Saharan Africa. The majority 
of society affected by cryptococcsis is socio-economically low and is often responsible for the 
support and care of others (Quinn, 1996). In this region, prospective studies on cryptococal 
pulmonary infections are needed so that appropriate therapy can be initiated, thus reducing the 
incidence of opportunistic infections. 
The goal of this study was to determine the prevalence of pulmonary cryptococcsis, 
and define clinical presentations in HIV/AIDS patients in Jos city, Nigeria. We showed that 
cryptococcsis is a major pulmonary marker in HIV/AIDS patients, presenting with systemic 
pneumonia.  
 
Materials and Methods  
Study Population 
 
 Human immunodeficiency Virus/Acquired immunodefiency syndrome (HIV/AIDS) 
patients were recruited for this study. The patients were attending Faith Alive Foundation 
Clinic, Jos, for support, care and highly active antiretroviral therapy (HAART). The study was 
in accordance with Helsinki declaration. 
Sample collection: Early morning sputum was collected from each patient, after due 
counseling and instructions (Beneke and Rogers, 1996; Robinson and Pachye, 1988). The 
consistency and cellular make-up of the sputum was used to determine the quality of the 
samples ensuring that the specimens were expectorated from deep within the lungs. 
Cultural methods: The sputum was routinely plated onto thistle Baird seed agar, sheep blood 
agar, Brainheart infusion both, brainheart infusion agar and Sabouraud dextrose agar. All 
cryptococcal isolates were sub-cultured onto Sabouraud dextrose agar and thistle Baird seed 
agar, and their identity was confirmed with API 20C kits (Biomereux, France). 
 
Study Definitions 
 
The patients were classified as either having pulmonary cryptococcosis or 
disseminated C. neoformans. The criteria used for pulmonary cryptoccosis in this report are: 
(1) Certainty of diagnosis; the isolation of C. neoformans from the sputum samples, with 
radiographic evidence of disease and clinical symptoms; (2) Colonization, was identified on 
the basis of isolation of C. neoformans in respiratory specimen with either a normal chest 
radiograph or asymptomatic State with abnormal radiograph. The sites of involvement were 
classified as pulmonary because only the lungs and/or pleura were the sites involved. 
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Results 
 
Two hundred and fifty patients with HIV/AIDS infection, and proven evidence of 
lung abnormality were enrolled for this study. Respiratory specimens were not collected from 
the patients that did not meet-up the study criteria, after reviewing the medical records. Out of 
250 patients who met the study criteria, 47(18.8%) had pulmonary colonization with C. 
neoformans, (pulmonary cryptococcosis); 15 (6.0%) had possible disease while 188 (75.2%) 
either had growth or no C. neoformans was isolated. 
 
Demographic characteristics 
 
 The subjects were made–up of 102 (40.8%) males and 148 (59.2%) females. 
Pulmonary cryptococcosis was confirmed in 21 (8.4%) males and 26 (10.4%) females. The 
age group of 20-40 years old was 209 (83.6%), with 39 (15.6%) isolates of C. neoformans 
only 8(3.2%) isolates were from the elderly patients. The duration of HIV/AIDS infection 
showed that those with prolonged AIDS has more yield of C. neoformans (13.6% Vs 5.2%) 
(Table 1). 
 The clinical signs and symptoms attributable to cryptococcosis and observed in the 
patients at the time of diagnosis varied from one patient to another (Table 2). Overall the 
patients with purulent and bloody sputum production has 43% yield of pulmonary 
colonization while those with fever has 36% yields. Those without any specific clinical 
symptoms had 26% of pulmonary cryptococosis. 
 The patients on therapy options were analyzed. Those on HAART regimens had 
lower yields, while those who has not started HAART regimens, but may have abused 
antibiotics in treating opportunistic infections and those who experimented the use of local 
herbs for cure yielded higher isolates of C neoformans, (26% Vs 40%)  The patients, who had 
not started therapy, gave a yield of 23%. These are group of patients from rural communities 
who came for treatment of pneumonia and were diagnosed of HIV infection, in the patients 
stuttering from other opportunistic infections (Data not shown), 87% of C. neoformans were 
isolated, while those that have no other opportunistic infections had 13% of isolates of C 
neoformans. 
 
 
Table 1: Demographic characteristics of 250 patients suspected of pulmonary cryptoccoial 
infections. 
 
Characteristics  N = 250 Positive isolates (%) 
Sex:   
Male  102 (40.8) 21 (8.4) 
Female  148 (59.2) 26 (10.4) 
AGE  
< 20 
 
5 
 
0 (0) 
20 –40 209 39 (15.6) 
> 40 36 8 (3.2) 
Duration of HIV infection 
(years)  
  
1 – 5 121 13 (5.2) 
6 – 10 104 20 (8.0) 
11+ 25 14 (5.6) 
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Table 2: Presenting clinical characteristics of 47 isolated pulmonary cryptococcosis. 
Characteristics  
 General:                          
No (%) 
Fever 17 (36) 
Night sweats  11 (23) 
Fatigue 2 (4) 
Lack of appetite  3 (6) 
Weight loss 6 (13) 
Malaise  6 (13) 
Headache  2 (4) 
Pulmonary  
Cough 9 (19) 
Chest pain 6 (13) 
Sputum production  20 (43) 
None 12 (26) 
Patients on Therapy:  
HAART  5 (11) 
Local herbs  12 (26) 
Antibiotics  19 (40) 
None 11 (23) 
Presence of other opportunistic infection:  
Yes  41 (87) 
No  6 (13) 
 
 
 
Discussion  
  
Cryptococcosis has emerged as defining feature for HIV/AIDS infection. The 
occurrence of pulmonary cryptococcosis can range from asymptomatic nodular disease to 
severe acute distress syndrome (ARDS) (Saag et al., 2000; Warkentine et al., 2000). The 
epidemiological trends of infection with C. noefomans can only be evaluated through 
surveillance studies (Dromer et al., 2004). This study was aimed to determine the prevalence 
of primary pulmonary cryptococcosis in AIDS patients with isolated cases of pulmonary 
pneumonia. All subjects enrolled in the study were confirmed HIV–positive and presenting 
with AIDS–defining-illness, and CD4+count ≤ 200/mm2 (CDC). Of 250 patients enrolled in 
this survey, 47 (18.8%) had primary lung infections due to C neoformans. Batungwanayo et al  
(1994) reported higher primary pulmonary cryptococcosis in Rwanda. In a study of 37 AIDS 
patients; 29 (78%) had pulmonary cryptococcosis. It is assumed that C neoformans generally 
gains access to the host by inhalation and the respiratory system is the usual portal of entry 
(Aberg et al., 1999). Therefore, colonization of the lungs is expected hence the high isolation 
of C. neoformans from HIV/AIDS patients. In the normal host, inhalation of organism is 
followed by localized immunologic response that contains the organism before symptoms or 
dissemination occurs (Warkentine et al., 2000). Since the AIDS patients are 
immunocompromised, dissemination of the disease will be a common characteristic. 
 The demographic characteristics indicate that the females were more infected than 
the males. This gender difference may be as result of certain factors such as; the patients not 
availing themselves for medical care on time or considering themselves not at risk for HIV-
infection or in patients with poor access to care (Mirza et al., 2003).  This is reflected in the 
duration of HIV/AIDS infection, as those with long-term infection AIDS had more isolates of 
C neoformans than those with shorter duration. It can be explained by the fact that C 
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neoformans infection may be initially asymptomatic but progresses as the patients CD4+ cell 
count declines.  
C neoformans infection have high incidence and is the liter- threatening fungal 
pathogen most communally seen in AIDS patients (Dismukes, 1998). Cryptococcal 
pneumonia may present with or without evidence of dissemination. It is unclear if 
disseminated disease represents a progression or reactivation of pulmonary disease because 
many patients have no evidence of pulmonary involvement at the time of diagnosis of 
disseminated disease. Our study showed that those with fever, night sweats, weight loss and 
malaise gave higher isolates of C. neoformans. It was observed that patients with pulmonary 
cough, chest pain and produces bloody sputum had high yields of C. neoformans. The 
asymptomatic patients with an isolate of 26% indicate the clinical variable nature of the 
pulmonary cryptocccosis. The conditions of such AIDS patients are likely to worsen in 
absence of treatment. Taken together, dissemination of the disease to central nervous system 
due to cryptococcal invasion will be a common feature thereby causing crytococcal 
meningitis. There is high morbidity and mortality of such cryptococcal meningitis. This is 
illustrated in the study of Heyderman et al. (1998) in Zimbabwe, where anti-fungal therapy 
was not available. Their work showed that cryptococcal meningitis was the AIDS defining 
illness in 88% of the patients.   
The management of HIV/AIDS disease is dependent on the suppression of viral 
replications and on the ability to preserve and restore immune function. Highly active 
antiretroviral therapy (HAART) results in longer term of virus load reduction (Hammer et al., 
1997; Gulizk et al, 1997). The clinical benefit from HAART is increased CD4 lymphocyte 
and thus immune system restoration. This decreases the frequency of opportunistic infections. 
In this study, 11% isolates of C. neoformans were from the patients on HAART. Those on 
local herb mediations, self-prescribed antibiotics and those that are not on therapy have 
combined isolation rate of 89%. This indicates that cryptococcosis continues to occur, but 
primarily in patients availing themselves less to routine medical care and whereas those 
patients with higher C. neoformans isolates may have been as result of reticence and 
ignorance (Mirza et al, 2003).          
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